U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institute of Neurological Disorders and Stroke (NINDS) <https://www.ninds.nih.gov/>
For Immediate Release: Friday, May 3, 2019
CONTACT: Carl P. Wonders, Ph.D., (301) 496-5751, <e-mail:nindspressteam@xxxxxxxxxxxxx>
MEDIA ADVISORY
NIH-FUNDED TRIAL OF ISRADIPINE SHOWS NO BENEFIT FOR PARKINSON’S DISEASE TREATMENT
STEADY-PD trial involved nearly 350 study participants at 54 sites
WHAT:
Isradipine, a drug approved for treating high blood pressure, has previously shown promise in slowing the progression of Parkinson’s disease in preclinical and early, small clinical studies. In a follow up study supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, the STEADY-PD phase 3 clinical trial looked at the benefit of a three-year isradipine treatment regimen. The primary results show that people who took 10 milligrams daily of isradipine had no difference in the progression of their Parkinson’s disease symptoms compared to others who took a placebo.
The size and high retention rate of the study—95 percent of the nearly 350 participants across 54 sites—means that, while a negative result, researchers can be confident in the findings and use them in future studies looking at avenues for slowing or halting the progression of Parkinson’s disease. These results will be presented at the Clinical Trials Plenary Session of the American Academy of Neurology’s 71st Annual Meeting on May 7, 2019, at 9:15 a.m. EDT.
WHO:
Walter Koroshetz, M.D., NINDS Director and Codrin Lungu, M.D., program director, Division of Clinical Research, NINDS are available to comment on this study.
CONTACT:
To schedule interviews, please contact nindspressteam@xxxxxxxxxxxxx
Presentation:
Simuni et al. “A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): final study results” May 7, 2019, American Academy of Neurology 71st Annual Meeting.
This study was supported by NINDS (NS080818); some biosample collections and the preceding phase 2 study were funded by The Michael J. Fox Foundation for Parkinson's Research.
NINDS (http://www.ninds.nih.gov) is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
To subscribe (or unsubscribe) from NIH News Release mailings, go to
<http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>.
If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>.
